These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

175 related articles for article (PubMed ID: 34058748)

  • 1. Birth Weight- or Gestational Age-adjusted Second-tier LCMSMS Cutoffs Improve Newborn Screening for CAH in New Zealand.
    de Hora MR; Heather NL; Webster D; Albert BB; Hofman PL
    J Clin Endocrinol Metab; 2021 Aug; 106(9):e3390-e3399. PubMed ID: 34058748
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Implementing steroid profiling by liquid chromatography-tandem mass spectrometry improves newborn screening for congenital adrenal hyperplasia in New Zealand.
    de Hora MR; Heather NL; Patel T; Bresnahan LG; Webster D; Hofman PL
    Clin Endocrinol (Oxf); 2021 Jun; 94(6):904-912. PubMed ID: 33471388
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Steroid profiling for congenital adrenal hyperplasia by tandem mass spectrometry as a second-tier test reduces follow-up burdens in a tertiary care hospital: a retrospective and prospective evaluation.
    Seo JY; Park HD; Kim JW; Oh HJ; Yang JS; Chang YS; Park WS; Lee SY
    J Perinat Med; 2014 Jan; 42(1):121-7. PubMed ID: 23989111
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Steroid profile in dried blood spots by liquid chromatography tandem mass spectrometry: Application to newborn screening for congenital adrenal hyperplasia in China.
    Zhan X; Han L; Qiu W; Gu X; Guo J; Chang S; Wang Y; Zhang H
    Steroids; 2022 Sep; 185():109056. PubMed ID: 35660382
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Steroid profiling by tandem mass spectrometry improves the positive predictive value of newborn screening for congenital adrenal hyperplasia.
    Minutti CZ; Lacey JM; Magera MJ; Hahn SH; McCann M; Schulze A; Cheillan D; Dorche C; Chace DH; Lymp JF; Zimmerman D; Rinaldo P; Matern D
    J Clin Endocrinol Metab; 2004 Aug; 89(8):3687-93. PubMed ID: 15292289
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Second-tier Testing for 21-Hydroxylase Deficiency in the Netherlands: A Newborn Screening Pilot Study.
    Stroek K; Ruiter A; van der Linde A; Ackermans M; Bouva MJ; Engel H; Jakobs B; Kemper EA; van den Akker ELT; van Albada ME; Bocca G; Finken MJJ; Hannema SE; Mieke Houdijk ECA; van der Kamp HJ; van Tellingen V; Paul van Trotsenburg AS; Zwaveling-Soonawala N; Bosch AM; de Jonge R; Heijboer AC; Claahsen-van der Grinten HL; Boelen A
    J Clin Endocrinol Metab; 2021 Oct; 106(11):e4487-e4496. PubMed ID: 34171085
    [TBL] [Abstract][Full Text] [Related]  

  • 7. International Newborn Screening Practices for the Early Detection of Congenital Adrenal Hyperplasia.
    Conlon TA; Hawkes CP; Brady JJ; Loeber JG; Murphy N
    Horm Res Paediatr; 2024; 97(2):113-125. PubMed ID: 37231960
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Neonatal Screening for Congenital Adrenal Hyperplasia in Turkey: A Pilot Study with 38,935 Infants.
    Güran T; Tezel B; Gürbüz F; Selver Eklioğlu B; Hatipoğlu N; Kara C; Şimşek E; Çizmecioğlu FM; Ozon A; Baş F; Aydın M; Darendeliler F
    J Clin Res Pediatr Endocrinol; 2019 Feb; 11(1):13-23. PubMed ID: 30111524
    [TBL] [Abstract][Full Text] [Related]  

  • 9. False positive rate in newborn screening for congenital adrenal hyperplasia (CAH)-ether extraction reveals two distinct reasons for elevated 17alpha-hydroxyprogesterone (17-OHP) values.
    Fingerhut R
    Steroids; 2009 Aug; 74(8):662-5. PubMed ID: 19463687
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Application of Principal Component Analysis to Newborn Screening for Congenital Adrenal Hyperplasia.
    Lasarev MR; Bialk ER; Allen DB; Held PK
    J Clin Endocrinol Metab; 2020 Aug; 105(8):. PubMed ID: 32525982
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Measurement of 17-Hydroxyprogesterone by LCMSMS Improves Newborn Screening for CAH Due to 21-Hydroxylase Deficiency in New Zealand.
    de Hora MR; Heather NL; Patel T; Bresnahan LG; Webster D; Hofman PL
    Int J Neonatal Screen; 2020 Mar; 6(1):6. PubMed ID: 33073005
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Use of steroid profiling by UPLC-MS/MS as a second tier test in newborn screening for congenital adrenal hyperplasia: the Utah experience.
    Schwarz E; Liu A; Randall H; Haslip C; Keune F; Murray M; Longo N; Pasquali M
    Pediatr Res; 2009 Aug; 66(2):230-5. PubMed ID: 19390483
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Newborn screening for congenital adrenal hyperplasia in Tokyo, Japan from 1989 to 2013: a retrospective population-based study.
    Tsuji A; Konishi K; Hasegawa S; Anazawa A; Onishi T; Ono M; Morio T; Kitagawa T; Kashimada K
    BMC Pediatr; 2015 Dec; 15():209. PubMed ID: 26671474
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Evaluation of a New Laboratory Protocol for Newborn Screening for Congenital Adrenal Hyperplasia in New Zealand.
    de Hora MR; Heather NL; Webster DR; Albert BB; Hofman PL
    Int J Neonatal Screen; 2022 Oct; 8(4):. PubMed ID: 36278626
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Determination of a steroid profile in heel prick blood using LC-MS/MS.
    Boelen A; Ruiter AF; Claahsen-van der Grinten HL; Endert E; Ackermans MT
    Bioanalysis; 2016; 8(5):375-84. PubMed ID: 26891684
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Newborn screening for congenital adrenal hyperplasia: additional steroid profile using liquid chromatography-tandem mass spectrometry.
    Janzen N; Peter M; Sander S; Steuerwald U; Terhardt M; Holtkamp U; Sander J
    J Clin Endocrinol Metab; 2007 Jul; 92(7):2581-9. PubMed ID: 17456574
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The adjustment of 17-hydroxyprogesterone cut-off values for congenital adrenal hyperplasia neonatal screening by GSP according to gestational age and age at sampling.
    Jiang X; Tang F; Feng Y; Li B; Jia X; Tang C; Liu S; Huang Y
    J Pediatr Endocrinol Metab; 2019 Nov; 32(11):1253-1258. PubMed ID: 31603856
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Twenty Years of Neonatal Screening for Congenital Adrenal Hyperplasia in North-Eastern Italy: Role of Liquid Chromatography-Tandem Mass Spectrometry as a Second-Tier Test.
    Cavarzere P; Camilot M; Palma L; Lauriola S; Gaudino R; Vincenzi M; Antoniazzi F; Teofoli F; Piacentini G
    Horm Res Paediatr; 2022; 95(3):255-263. PubMed ID: 35350013
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Improved precision of newborn screening for congenital adrenal hyperplasia using weight-adjusted criteria for 17-hydroxyprogesterone levels.
    Allen DB; Hoffman GL; Fitzpatrick P; Laessig R; Maby S; Slyper A
    J Pediatr; 1997 Jan; 130(1):128-33. PubMed ID: 9003862
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Neonatal Screening for Congenital Adrenal Hyperplasia in Turkey: Outcomes of Extended Pilot Study in 241,083 Infants.
    Güran T; Tezel B; Çakır M; Akıncı A; Orbak Z; Keskin M; Selver Eklioğlu B; Ozon A; Özbek MN; Karagüzel G; Hatipoğlu N; Gürbüz F; Çizmecioğlu FM; Kara C; Şimşek E; Baş F; Aydın M; Darendeliler F
    J Clin Res Pediatr Endocrinol; 2020 Sep; 12(3):287-294. PubMed ID: 32157855
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.